Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more
Xvivo Perfusion AB (publ) (XVIPF) - Net Assets
Latest net assets as of December 2025: $2.11 Billion USD
Based on the latest financial reports, Xvivo Perfusion AB (publ) (XVIPF) has net assets worth $2.11 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.37 Billion) and total liabilities ($260.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.11 Billion |
| % of Total Assets | 89.02% |
| Annual Growth Rate | 27.59% |
| 5-Year Change | 64.0% |
| 10-Year Change | 566.27% |
| Growth Volatility | 29.37 |
Xvivo Perfusion AB (publ) - Net Assets Trend (2012–2025)
This chart illustrates how Xvivo Perfusion AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xvivo Perfusion AB (publ) (2012–2025)
The table below shows the annual net assets of Xvivo Perfusion AB (publ) from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $2.11 Billion | -2.25% |
| 2024-12-31 | $2.16 Billion | +10.89% |
| 2023-12-31 | $1.95 Billion | +36.00% |
| 2022-12-31 | $1.43 Billion | +11.26% |
| 2021-12-31 | $1.29 Billion | +27.47% |
| 2020-12-31 | $1.01 Billion | +74.62% |
| 2019-12-31 | $577.52 Million | +6.85% |
| 2018-12-31 | $540.48 Million | +7.17% |
| 2017-12-31 | $504.33 Million | +59.39% |
| 2016-12-31 | $316.41 Million | +71.15% |
| 2015-12-31 | $184.87 Million | +4.93% |
| 2014-12-31 | $176.18 Million | +82.32% |
| 2013-12-31 | $96.64 Million | +8.87% |
| 2012-12-31 | $88.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xvivo Perfusion AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 279.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $316.11 Million | 14.99% |
| Common Stock | $816.94K | 0.04% |
| Other Comprehensive Income | $10.63 Million | 0.50% |
| Other Components | $1.78 Billion | 84.46% |
| Total Equity | $2.11 Billion | 100.00% |
Xvivo Perfusion AB (publ) Competitors by Market Cap
The table below lists competitors of Xvivo Perfusion AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rupert Resources Ltd
OTCQX:RUPRF
|
$608.42 Million |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
$608.91 Million |
|
GungHo Online Entertainment Inc
OTCGREY:GUNGF
|
$609.17 Million |
|
SandRidge Energy Inc
NYSE:SD
|
$609.22 Million |
|
Salfacorp
SN:SALFACORP
|
$607.92 Million |
|
Hunan New Wellful Co Ltd
SHG:600975
|
$607.92 Million |
|
Wiscom System Co Ltd
SHE:002090
|
$607.71 Million |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
$607.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xvivo Perfusion AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,156,778,000 to 2,108,157,321, a change of -48,620,679 (-2.3%).
- Net income of 25,099,872 contributed positively to equity growth.
- Other comprehensive income increased equity by 10,627,266.
- Other factors decreased equity by 84,347,817.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $25.10 Million | +1.19% |
| Other Comprehensive Income | $10.63 Million | +0.5% |
| Other Changes | $-84.35 Million | -4.0% |
| Total Change | $- | -2.25% |
Book Value vs Market Value Analysis
This analysis compares Xvivo Perfusion AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.40x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.84x to 0.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $4.54 | $26.50 | x |
| 2013-12-31 | $4.94 | $26.50 | x |
| 2014-12-31 | $8.50 | $26.50 | x |
| 2015-12-31 | $8.57 | $26.50 | x |
| 2016-12-31 | $13.89 | $26.50 | x |
| 2017-12-31 | $19.63 | $26.50 | x |
| 2018-12-31 | $20.55 | $26.50 | x |
| 2019-12-31 | $21.55 | $26.50 | x |
| 2020-12-31 | $37.11 | $26.50 | x |
| 2021-12-31 | $44.42 | $26.50 | x |
| 2022-12-31 | $48.44 | $26.50 | x |
| 2023-12-31 | $64.98 | $26.50 | x |
| 2024-12-31 | $68.14 | $26.50 | x |
| 2025-12-31 | $66.80 | $26.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xvivo Perfusion AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.10%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.12x
- Recent ROE (1.19%) is below the historical average (2.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -0.87% | -5.22% | 0.13x | 1.29x | $-9.65 Million |
| 2013 | 8.33% | 11.69% | 0.54x | 1.32x | $-1.61 Million |
| 2014 | 2.12% | 4.41% | 0.42x | 1.14x | $-13.88 Million |
| 2015 | 2.78% | 4.27% | 0.59x | 1.10x | $-13.36 Million |
| 2016 | 0.47% | 1.09% | 0.40x | 1.10x | $-30.14 Million |
| 2017 | 1.24% | 4.22% | 0.28x | 1.07x | $-44.17 Million |
| 2018 | 2.35% | 6.75% | 0.32x | 1.09x | $-41.36 Million |
| 2019 | 0.86% | 2.24% | 0.35x | 1.10x | $-52.81 Million |
| 2020 | -4.34% | -24.32% | 0.16x | 1.14x | $-144.58 Million |
| 2021 | 0.63% | 3.15% | 0.17x | 1.20x | $-120.39 Million |
| 2022 | 1.29% | 4.44% | 0.24x | 1.21x | $-124.59 Million |
| 2023 | 4.72% | 15.37% | 0.27x | 1.13x | $-102.68 Million |
| 2024 | 7.98% | 20.94% | 0.34x | 1.11x | $-43.50 Million |
| 2025 | 1.19% | 3.10% | 0.34x | 1.12x | $-185.72 Million |
Industry Comparison
This section compares Xvivo Perfusion AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xvivo Perfusion AB (publ) (XVIPF) | $2.11 Billion | -0.87% | 0.12x | $607.94 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |